Pyzchiva (ustekinumab-ttwe) / Samsung, Sandoz, NIPRO Corp - LARVOL DELTA

Short and medium-term outcomes of ustekinumab biosimilar in patients with Crohn’s Disease (ECCO-IBD 2026) - "No adverse event was observed. Conclusion Administration of the ustekinumab biosimilar appears to be both safe and effective when initiated in UST-naive patients or following switch from originator ustekinumab in CD patients."

Clinical • Crohn's disease • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Switching from ustekinumab originator to biosimilar: No adverse impact on inflammatory bowel disease control and well tolerated by patients in a UK multicentre study (ECCO-IBD 2026) - "Prior treatment exposure was anti-tumour necrosis factor agents (anti-TNF) in 440 (81%) patients, vedolizumab in 89 (16%) patients and both anti-TNF and vedolizumab in 65 (12%) patients. Biosimilar ustekinumab was well tolerated and appears to be safe. Biosimilar evaluation will continue with the 12-month review of this cohort."

Clinical • Crohn's disease • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • CRP

Risankizumab versus reference and biosimilar ustekinumab in moderate-to-severe Crohn’s disease: A cost-effectiveness model from the German perspective (ECCO-IBD 2026) - "Sensitivity analysis showed at a willingness to pay threshold of €35,000 (assumed to be NICE upper threshold of £30,000 converted to Euros), the probability of risankizumab being cost-effective was 0% compared to both reference and biosimilar ustekinumab (Figure 1). Conclusion Using clinical data from SEQUENCE trial, results from the cost-effectiveness model indicate that reference ustekinumab is more cost effective than risankizumab for moderate-to-severe CD with previous TNFα failure, which is more marked with biosimilar ustekinumab due to lower cost."

Cost effectiveness • HEOR • Crohn's disease • Immunology • Inflammatory Bowel Disease • IL12A • TNFA

Samsung Bioepis…announced on the 14th that the pre-filled pen formulation (PFP) of the autoimmune disease treatment Stelara biosimilar 'Epiztec (ingredient: ustekinumab)' received product approval from the Ministry of Food and Drug Safety on the 13th. [Google translation] (HIT News)

Korea approval • Crohn's disease • Psoriasis • Psoriatic Arthritis • Ulcerative Colitis

Samsung Bioepis…announced the marketing approval of Ustekinumab BS Subcutaneous Injection 45mg Syringes 'NIPRO', a biosimilar referencing Stelara (ustekinumab), developed by Samsung Bioepis (Businesswire) - "‘NIPRO’ has been approved for the treatment of plaque psoriasis, and psoriatic arthritis. The product is set to be listed in the Japan’s National Health Insurance (NHI) drug list in May 2026, allowing for commercialization by NIPRO immediately after drug listing."

Biosimilar launch • Japan approval • Psoriasis • Psoriatic Arthritis

Pyzchiva (ustekinumab-ttwe): A New Biosimilar for Psoriasis. (PubMed, Ann Pharmacother) - "Ustekinumab-ttwe's equivalence to its reference biologic ustekinumab creates another treatment option for patients with moderate- to- severe plaque psoriasis."

Journal • Review • Dermatology • Immunology • Psoriasis

Samsung Bioepis Reaches Settlement Agreement for PYZCHIVA (ustekinumab) in Europe (Business Korea)

Commercial • Crohn's disease • Psoriasis • Psoriatic Arthritis • Ulcerative Colitis

Similarity of efficacy of SB17 to reference ustekinumab for moderate-to-severe psoriasis through 12 weeks in different demographic and comorbidity subgroups (encore) (EADV 2025) - P3 | "SB17 had comparable efficacy to UST irrespective of baseline weight, BMI, disease duration, history of PsA, and prior exposure to biologic therapy at week 12."

Clinical • Dermatology • Immunology • Psoriasis

Analytical Data and Single-Dose PK are Sufficient to Conclude Comparable Immunogenicity for Biosimilars: An Ustekinumab Case Study. (PubMed, BioDrugs) - "The comparative clinical efficacy studies revealed no additional information. This finding adds on to the evidence that clinical PK and the comparative analytical assessment, specifically the comparison of quality attributes with potential immunogenic relevance, suffice for the evaluation of immunogenicity of biosimilars in general."

Journal • Review

Samsung Bioepis enters Japanese market through partnership (KoreaTimes) - "Korean biosimilar developer Samsung Bioepis said Monday it will make its entry into the Japanese market through a partnership with a Japanese health care company. According to Samsung Bioepis, it has entered into a license, development and commercialization agreement in Japan with NIPRO for Bioepis’ multiple biosimilar candidates, including autoimmune disease biosimilar SB17....Under the terms of the agreement, Samsung Bioepis will be responsible for the development, manufacture and supply of the medicines, while NIPRO will be responsible for their commercialization in Japan."

Licensing / partnership • Crohn's disease • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Ulcerative Colitis

Mirikizumab (Omvoh) - an IL-23 antagonist for Crohn's disease. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease • IL23A

The "totality of evidence" and "extrapolation" of SB17, a ustekinumab biosimilar. (PubMed, Expert Opin Biol Ther) - "Despite their potential to transform clinical outcomes, economic burdens, and drug utilization patterns, the adoption of UST biosimilars faces challenges, including concerns about equivalence and regulatory inconsistencies. Addressing these issues through education, consistent regulatory frameworks, real-world data, and ongoing monitoring is crucial for their successful integration into clinical practice."

Journal • Review • Crohn's disease • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Ulcerative Colitis • IL12A

Sandoz launches Pyzchiva autoinjector, first commercially available in Europe for ustekinumab biosimilars (GlobeNewswire) - "Sandoz...today announced the European launch of its Pyzchiva (ustekinumab) autoinjector. This is the first ustekinumab biosimilar in Europe commercially available in an autoinjector. Developed and registered by Samsung Bioepis, Pyzchiva is approved for the treatment of adults with plaque psoriasis, psoriatic arthritis, Crohn’s disease and pediatric plaque psoriasis for patients aged six years and older, weighing over 60 kg."

Launch Europe • Crohn's disease • Psoriasis • Psoriatic Arthritis

Samsung Bioepis Wins Legal Battle Over Stelara Biosimilar (Business Korea) - "Samsung Bioepis’ biosimilar Pyzchiva, a version of Stelara (treatment for autoimmune diseases), has been cleared for sale under Pharmacy Benefit Manager (PBM) subsidiary brands in the United States. According to industry sources on April 30, the U.S. District Court of New Jersey rejected on April 28 (local time) global pharmaceutical company Johnson & Johnson (J&J)'s request for an injunction against Samsung Bioepis to prohibit sales under PBM subsidiary brands. This decision allows Samsung Bioepis to launch private label products of Pyzchiva in the U.S. market. J&J filed for the injunction in February, claiming that it did not grant Samsung Bioepis the authority to launch private label products in the Stelara biosimilar agreement."

Corporate lawsuit • Crohn's disease • Inflammatory Bowel Disease • Psoriasis • Psoriatic Arthritis • Ulcerative Colitis

[Exclusive] Danish Court "Janssen Appeal Dismissed"⋯Samsung Bioepis Wins 'Pyzchiva' Dispute (Seoul Wire) - "Janssen's appeal against the Danish patent infringement of Samsung Bioepis' Stelara biosimilar 'Pyzchiva (ingredient name: ustekinumab, development code name: SB17)' has been dismissed...On the 10th (local time), the 10th Division of the Eastern High Court of Denmark ruled on Janssen Biotech's appeal of the temporary injunction and order on Pyzchiva against Samsung Bioepis NL BV and contract manufacturing organization (CMO) company AGC Biologics A/S (AGC)...The EP 606 patent covers the dosing regimen and clinical results of Stelara, the original product of Pyzchiva, for the treatment of ulcerative colitis (UC). The priority date of this patent is November 20, 2018 and the expiration date is September 24, 2039. Janssen also owns the 'DK 202300038 Utility Model (hereinafter referred to as 038 Utility Model)' which is identical to the EP 606 patent."

Patent • Ulcerative Colitis

Samsung Bioepis projects $580 mil. in EU cost savings as Stelara biosimilar gains ground (Korea Biomedical Review) - "With patent walls down on the blockbuster immunology drug Stelara, Samsung Bioepis is making its move. Backed by a courtroom win in Europe and new budget impact data, the Korean biosimilar maker is projecting more than €526 million ($580 million) in cost savings across Germany, the U.K., and Sweden over three years by switching to its ustekinumab biosimilar, Pyzchiva....In Germany alone, the model shows Pyzchiva could save €440 million—driven by annual per-patient savings topping €5,000 and a 72 percent uptake rate."

HEOR • Immunology

Similarity of efficacy of SB17 to reference ustekinumab for moderate-to-severe psoriasis through 12 weeks in different demographic and comorbidity subgroups (AAD 2025) - P3 | "SB17 had comparable efficacy to UST irrespective of baseline weight, BMI, disease duration, history of PsA, and prior exposure to biologic therapy at week 12."

Clinical • Dermatology • Immunology • Psoriasis

Sandoz reports strong FY 2024 results and Q4 2024 sales (GlobeNewswire) - "Net sales for the fourth quarter were USD 769 million, up 25% in constant currencies. Net sales for the full year were USD 2.9 billion, up 30% in constant currencies. The biosimilars share of total net sales increased from 23% in FY 2023 to 28% in FY 2024. The strong double-digit biosimilars growth reflects the uptake of Hyrimoz in the US through the private- label agreement with...the Sandoz Hyrimoz and unbranded adalimumab-adaz. In addition...the continued strong demand for the first-ever biosimilar...and the launches of Tyruko and Pyzchiva in Europe all contributed to the strong performance."

Sales • Hidradenitis Suppurativa • Immunology • Inflammatory Bowel Disease • Ophthalmology • Rheumatoid Arthritis

Samsung Bioepis Announces US Launch of PYZCHIVA (ustekinumab-ttwe), Biosimilar to Stelara (Businesswire) - "Samsung Bioepis Co., Ltd. today announced that PYZCHIVA (ustekinumab-ttwe), a biosimilar to Stelara (ustekinumab), is now available in the United States. PYZCHIVA has been approved for the treatment of moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, active psoriatic arthritis, moderately to severely active Crohn's disease, and moderately to severely active ulcerative colitis. Through Samsung Bioepis’ commercialization partner Sandoz, PYZCHIVA is available to patients across US starting today in 45 mg/0.5 mL and 90 mg/mL pre-filled syringes, 130 mg/26 mL intravenous infusion single-dose vial, and 45 mg/0.5 mL subcutaneous vials....In the US, the license period for PYZCHIVA will begin on February 22, 2025, according to the settlement and license agreement between Samsung Bioepis and Janssen Biotech Inc."

Biosimilar launch • Crohn's disease • Immunology • Psoriasis • Psoriatic Arthritis • Ulcerative Colitis

Sandoz launches biosimilar Pyzchiva (ustekinumab) across Europe, to treat chronic inflammatory diseases (GlobeNewswire) - "Sandoz...announces the launch of Pyzchiva (ustekinumab) across Europe, starting today. Pyzchiva, developed and registered by Samsung Bioepis, is the first ustekinumab biosimilar to launch in Europe with all reference medicine strengths, including the 130mg vial initiation dose for Crohn’s disease."

Biosimilar launch • Crohn's disease • Immunology • Inflammation

Characterization for the Similarity Assessment Between the Proposed Biosimilar SB17 and Ustekinumab Reference Product Using State-of-the-Art Analytical Methods. (PubMed, Drugs R D) - "In summary, the overall analytical characterization and similarity assessment results show that SB17 is comparable to the EU and US ustekinumab RP in terms of structural, physicochemical, biophysical, and biological attributes."

Journal • Inflammation • IL12A

Biosimilar SB17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52. (PubMed, J Dermatolog Treat) - "The incidence of treatment-emergent adverse events (SB17 + SB17: 16.5%, UST+SB17: 13.9%, UST+UST: 23.8%) and the overall incidence of anti-drug antibodies occurring after transition were comparable between treatment groups (SB17 + SB17: 5.6%, UST+SB17: 5.1%, and UST+UST: 6.7%). SB17 demonstrated clinical biosimilarity to UST after switching from UST, and maintained long-term comparable efficacy and safety with UST up to Week 52."

Clinical • Journal • P3 data • Dermatology • Immunology • Psoriasis

Budget Impact Analysis to Assess Potential Cost Savings From the Introduction of Ustekinumab Biosimilars in Germany, the UK, and Sweden (ISPOR-EU 2024) - "The introduction of ustekinumab biosimilars provides a significant opportunity for payers to reduce budgetary pressures and improve treatment accessibility across the UK, Germany, and Sweden. It should be noted that this analysis did not cover patients with moderate-to-severe ulcerative colitis, as the indication is still under patent protection for the reference medicine."

HEOR • Crohn's disease • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Ulcerative Colitis • IL12A

Sandoz reports second-quarter sales and half-year 2024 results (GlobeNewswire) - "In recent months, we saw strong uptake of Hyrimoz in the US, received approval for Pyzchiva (ustekinumab) and Wyost/Jubbonti (denosumab) in the US and Europe and secured a settlement agreement in the US with launch dates in the first half of 2025....Total cash and cash equivalents decreased to USD 0.7 billion on June 30, 2024, compared to USD 1.1 billion on December 31, 2023. Net cash flows from operating activities were more than offset by our first dividend payment of USD 215 million and the Cimerli acquisition of USD 188 million."

Biosimilar launch • Commercial • Age-related Macular Degeneration • Crohn's disease • Immunology • Inflammatory Bowel Disease • Macular Degeneration • Ophthalmology • Osteoporosis • Psoriasis • Ulcerative Colitis • Wet Age-related Macular Degeneration

‘Totality-of-the-evidence’ of proposed ustekinumab biosimilar SB17’ (BSG 2024) - "In a phase III study of patients with moderate-to-severe PsO (Feldman, et al., EADV 2023. P0720), SB17 had equivalent efficacy, comparable safety and immunogenicity to UST-RP up to Week 28.Conclusion With similar target binding and PK and confirmed similarity in efficacy and safety for PsO patients, SB17 is proposed to be highly similar to UST-RP in physicochemical, non-clinical, and clinical studies and data supports its extrapolation to UST-RP indications."

Dermatology • Immunology • Psoriasis • IL12A